by Admin | Nov 30, 2022 | Portfolio News
Funding will support development of lead assets and enhance target discovery and platform development CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ — Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led...
by Admin | Nov 3, 2022 | Portfolio News
Boston/Shanghai/November 3rd, 2022 — Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004...
by Admin | Oct 14, 2022 | Portfolio News
美国圣地亚哥,中国上海、广东松山湖 2022年10月14日,专注于肿瘤领域的临床阶段生物技术公司凡恩世公司(Phanes Therapeutics)今天宣布,其DLL3/CD47双特异性抗体(双抗)PT217获得美国食品药品监督管理局(FDA)临床试验批准,将在小细胞肺癌(SCLC)和其他神经内分泌癌患者中开展I期临床试验。PT217近期也已获FDA孤儿药资格认定。...
by Admin | Aug 30, 2022 | Portfolio News
— 12 to 61-fold increase in neutralizing antibodies against BA.5 among participants receiving SCB-2019 (CpG 1018/Alum) as a homologous third dose or with a history of prior SARS-CoV-2 infection — — BA.5 neutralizing antibody levels were approximately...
by Admin | Aug 29, 2022 | Portfolio News
SAN DIEGO, Aug. 23, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study...
by Admin | Aug 29, 2022 | Portfolio News
— SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) — — Favorable tolerability and safety profile in adolescents,...